Literature DB >> 11033355

Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity.

L De Petrocellis1, T Bisogno, J B Davis, R G Pertwee, V Di Marzo.   

Abstract

Some synthetic agonists of the VR1 vanilloid (capsaicin) receptor also inhibit the facilitated transport into cells of the endogenous cannabinoid anandamide (arachidonoylethanolamide, AEA). Here we tested several AEA derivatives containing various derivatized phenyl groups or different alkyl chains as either inhibitors of the AEA membrane transporter (AMT) in intact cells or functional agonists of the VR1 vanilloid receptor in HEK cells transfected with the human VR1. We found that four known AMT inhibitors, AM404, arvanil, olvanil and linvanil, activate VR1 receptors at concentrations 400-10000-fold lower than those necessary to inhibit the AMT. However, we also found three novel AEA derivatives, named VDM11, VDM12 and VDM13, which inhibit the AMT as potently as AM404 but exhibit little or no agonist activity at hVR1. These compounds are weak inhibitors of AEA enzymatic hydrolysis and poor CB(1)/CB(2) receptor ligands. We show for the first time that, despite the overlap between the chemical moieties of AMT inhibitors and VR1 agonists, selective inhibitors of AEA uptake that do not activate VR1 (e.g. VDM11) can be developed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11033355     DOI: 10.1016/s0014-5793(00)02082-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  103 in total

Review 1.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

2.  Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport.

Authors:  Jennifer Ronesi; Gregory L Gerdeman; David M Lovinger
Journal:  J Neurosci       Date:  2004-02-18       Impact factor: 6.167

Review 3.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 4.  N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets.

Authors:  Mark Connor; Chris W Vaughan; Robert J Vandenberg
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 5.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

Review 6.  The Endocannabinoid System and its Modulation by Phytocannabinoids.

Authors:  Vincenzo Di Marzo; Fabiana Piscitelli
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

7.  Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH.

Authors:  Sandra Holt; Christopher J Fowler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-20       Impact factor: 3.000

Review 8.  Cellular accumulation of anandamide: consensus and controversy.

Authors:  Cecilia J Hillard; Abbas Jarrahian
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

9.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

Authors:  T Bisogno; L Hanus; L De Petrocellis; S Tchilibon; D E Ponde; I Brandi; A S Moriello; J B Davis; R Mechoulam; V Di Marzo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

10.  Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels.

Authors:  Mario van der Stelt; Marcello Trevisani; Vittorio Vellani; Luciano De Petrocellis; Aniello Schiano Moriello; Barbara Campi; Peter McNaughton; Piero Geppetti; Vincenzo Di Marzo
Journal:  EMBO J       Date:  2005-08-18       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.